CEPI Launches $3.6 Billion Strategy to Bolster Global Pandemic Defenses

The Coalition for Epidemic Preparedness Innovations (CEPI) has launched its new five-year strategy, CEPI 3.0, unveiling a bold plan to transform global preparedness against future epidemic and pandemic threats. The initiative calls for a total investment of US$3.6 billion, with US$1.1 billion already secured. CEPI is now seeking an additional US$2.5 billion from governments, philanthropies, and partners to fully implement this critical strategy. Unveiled on February 13, 2026, CEPI 3.0 is designed to commence in 2027 and build upon the lessons learned from the devastating COVID-19 pandemic. Dr. Richard Hatchett, CEO of CEPI, emphasized that the world 'paid the price of not being prepared' during COVID-19, and recent outbreaks of Nipah, Ebola, Chikungunya, and Marburg serve as powerful reminders of the constant threat posed by infectious diseases. The strategy's core objective is to systematically reduce the likelihood, impact, and cost of epidemics and pandemics by harnessing the latest scientific advances. A central pillar of CEPI 3.0 is the ambitious '100 Days Mission.' This game-changing goal aims to enable the world to develop safe, effective, and accessible vaccines against a novel virus with pandemic potential within just 100 days of its identification. Modelling suggests that if vaccines had been available within 100 days of COVID-19's identification, more than 8 million lives could have been saved, and trillions of dollars in global economic damage averted. This mission, endorsed by G7 and G20 leaders, represents one of the century's most significant public health undertakings. The CEPI 3.0 strategy outlines three interconnected priorities to achieve faster and fairer protection globally. These include developing vaccines for both known and emerging threats, advancing response-ready vaccines for menacing epidemic pathogens such as Lassa, Nipah, and Rift Valley fever, and generating scientific tools, data, and knowledge across viral families identified by the World Health Organization (WHO) as capable of causing public health emergencies. The plan also focuses on strengthening vaccine development across pathogens and viral families most likely to spark new outbreaks, advancing platform technologies adaptable to unknown threats, and creating innovative networks for research, manufacturing, and regulatory readiness to function as a unified global system. India plays a pivotal role in CEPI's global mission. As a founding investor in CEPI, India joined the coalition in 2017, recognizing the importance of combining national scientific expertise with global technological capabilities. India renewed its engagement strategy with CEPI, reinforcing its commitment to strengthening vaccine research, development, and pandemic preparedness. The partnership expands cooperation on emerging infectious diseases, infrastructure support, and rapid vaccine platforms. Initiatives include supporting training programs for skilled scientific personnel, enhancing biosafety and translational research capacity, and facilitating the development of several Indian vaccine candidates through CEPI-backed programs. India's robust R&D ecosystem and its established credentials as a reliable producer of quality and affordable vaccines make it a crucial partner in achieving CEPI's goals, particularly for ensuring equitable access to countermeasures. The 'Vax-Before-Travel' article, published on February 13, 2026, accurately reports on CEPI's funding appeal and strategic objectives. This source is a specialized publisher focusing on international vaccine information for travelers, claiming to provide fact-checked news reviewed by medical professionals. Its reporting on CEPI 3.0 aligns with official announcements from CEPI and other credible health news outlets. The news is highly relevant to a global audience, especially in India, given the country's critical role in vaccine manufacturing and its vulnerability to infectious disease outbreaks. CEPI 3.0 builds on the successes of its previous phases, CEPI 1.0 (2017-2021) and CEPI 2.0 (2022-2026). CEPI has supported over 50 vaccine candidates and 25 platform investments, co-led COVAX to deliver nearly 2 billion COVID-19 vaccine doses, and contributed to scientific breakthroughs for pathogens like Chikungunya, Nipah, and Lassa. The ongoing threat of new variants and the potential for 'Disease X' underscore the urgency for continued investment in pandemic preparedness. CEPI 3.0 is positioned as a critical global insurance policy, aiming to make epidemics and pandemics no longer an existential threat to humanity.

Frequently Asked Questions

Read Full Story on Quick Digest